Summary
Becton, Dickinson and Company (BDX) announced on October 2, 2024, that it has reached an agreement to resolve the vast majority of its existing hernia litigation. This settlement covers cases in both Rhode Island and federal multidistrict litigation in Ohio. Importantly, the aggregate amount payable under this settlement is within BD's current product litigation reserve and will not result in an incremental charge to the company's consolidated income statement. The settlement payments will be made over a multi-year period, a plan that was already factored into BD's cash flow projections and capital allocation strategy. BD emphasizes that the settlement does not involve any admission of liability or wrongdoing, and the company continues to dispute the allegations. BD intends to vigorously defend itself in any cases not covered by this agreement. Investors should note that while this settlement aims to bring closure to a significant portion of the litigation, BD will continue to defend against any outstanding or future claims not included in this resolution. The company's forward-looking statements regarding the settlement are subject to various uncertainties, including plaintiff participation levels and potential future litigation.
Key Highlights
- 1BDX has reached a settlement to resolve the majority of its existing hernia litigation.
- 2The settlement covers cases in Rhode Island and federal multidistrict litigation in Ohio.
- 3The total settlement amount is within BDX's existing product litigation reserve.
- 4The settlement will not result in an incremental charge to BDX's income statement.
- 5Payments will be made over a multi-year period, consistent with prior cash flow planning.
- 6BDX maintains it admits no liability or wrongdoing and will defend itself in remaining cases.
- 7The settlement's success is contingent on plaintiff participation and potential future claims.